Daniel Rabinowitz, an insider at Natera Inc (NTRA), has acquired 208,601 shares of the company at a price of $19.68 per share, amounting to a total transaction value of $4.11 million. This purchase took place on December 3, 2025, and following this transaction, Rabinowitz holds the same number of shares in the company.
Natera, headquartered in Austin, Texas, is a diagnostics firm specialising in genetic testing services. The company employs 4,424 full-time staff and went public on July 2, 2015. Its cfDNA technology platform integrates advanced molecular biology techniques with bioinformatics and artificial intelligence, leading to the development of non-invasive prenatal tests, tumour-specific assays, and various tests for organ health.
The company currently has a market capitalisation of $33.5 billion and an earnings per share (EPS) of -2.28. Upcoming earnings reports are scheduled for May 6, 2026, and August 5, 2026, with estimated EPS of -0.53 and -0.52, respectively.
Insider transactions, such as this one, are reported to the SEC and serve to provide transparency regarding the actions of company executives. While such buying activity may suggest confidence in the company’s future, it is essential for investors to consider broader patterns of insider activity rather than isolated transactions when evaluating these signals.